GlobeNewswire Inc.··NaAnaveon Pivots to Immunology, Touts ANV600 Data Ahead of ASCO 2026
Biotech firm Anaveon will present positive Phase 1 data for cancer drug ANV600 at ASCO 2026, actively seeking partners for legacy oncology portfolio.
PFENVSimmunotherapyASCO 2026